Fueled by four new product launches over the last two years, Genentech Inc. recorded a healthy first quarter in terms of both dollars and data. (BioWorld Today)

Prana Biotechnology Ltd.'s dreams of becoming a late-stage drug development company in 2005 suffered a blow Monday with the company's decision to cancel an upcoming Phase II/III trial of PBT1, a disease-modifying compound for Alzheimer's disease, due to manufacturing toxicity issues. (BioWorld International)